Richter and DM Bio agreement on technology transfer and license-in of biosimilar TrastuzumabTechnology Transfer and License Agreement • October 19th, 2016
Contract Type FiledOctober 19th, 2016Gedeon Richter Plc. (“Richter”) today announces that it has signed a technology transfer and license-in agreement with DM Bio (“DM Bio”) in respect of the development and commercialization of DM Bio’s biosimilar monoclonal antibody, Trastuzumab.